Utilizing Intra- and Peritumoral Radiomics to Assess Ambiguous HER2 Status in Breast Cancer via Contrast-Enhanced Mammography - Summary - MDSpire

Utilizing Intra- and Peritumoral Radiomics to Assess Ambiguous HER2 Status in Breast Cancer via Contrast-Enhanced Mammography

  • By

  • Cong Xu

  • Juan Qiu

  • Shijie Zhang

  • Yuqian Chen

  • Xiaodong Wang

  • Haicheng Zhang

  • Qi Wang

  • Tongpeng Chu

  • Ziyin Li

  • Peng Lu

  • Haizhu Xie

  • Heng Ma

  • Nina Qu

  • Ning Mao

  • Jing Liu

  • Runpeng Chen

  • Jing Gao

  • April 29, 2026

  • 0 min

Share

Objective:

To evaluate the equivocal HER2 (IHC 2+) status of breast cancer using intra- and peritumoral radiomics features of contrast-enhanced mammography (CEM), highlighting its significance for treatment decisions.

Key Findings:
  • The nomogram achieved optimal predictive performance with an AUC of 0.893 in the internal test cohort and 0.840 in the prospective test cohort, indicating strong predictive capability.
  • Incorporating intratumoral and peritumoral signatures along with clinical risk variables significantly improved prediction of equivocal HER2 status.
Interpretation:

The study suggests that a nomogram combining radiomics and clinical data can effectively predict equivocal HER2 status preoperatively, potentially reducing reliance on invasive FISH testing and improving patient management.

Limitations:
  • The study was conducted in a single institution, which may limit generalizability and introduce selection bias.
  • Further validation in larger, diverse cohorts is needed to confirm findings and enhance applicability.
Conclusion:

The nomogram has the potential to serve as a non-invasive tool for predicting equivocal HER2 status in breast cancer, aiding clinical decision-making.

Original Source(s)

Utilizing Intra- and Peritumoral Radiomics to Assess Ambiguous HER2 Status in Breast Cancer via Contrast-Enhanced Mammography

  • by Cong Xu, Juan Qiu, Shijie Zhang, Yuqian Chen, Xiaodong Wang, Haicheng Zhang, Qi Wang, Tongpeng Chu, Ziyin Li, Peng Lu, Haizhu Xie, Heng Ma, Nina Qu, Ning Mao, Jing Liu, Runpeng Chen, Jing Gao

  • April 29, 2026

Related Content

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications